A Research Tool’s Popularity Marches On
The Transgenic Adenocarcinoma Mouse Prostate (TRAMP) model is a transgenic line of C57BL/6 mice that develops histologic prostatic intraepithelial neoplasia by 8 to 12 weeks of age which progresses to adenocarcinoma with metastasis by 24 to 30 weeks of age. TRAMP was established using the minimal -426/+28 rat probasin promoter to target expression of the simian virus 40 large T antigen to prostatic epithelium. Three cell lines were established from the primary tumor in the prostate of a PB-Tag C57BL/6 (TRAMP) mouse and designated TRAMP-C1, TRAMP-C2, and TRAMP-C3. The mouse model and cell lines are useful for companies involved in prostate cancer research and are deposited at, and available for sale from, the Jackson Laboratories and ATCC, respectively, following a license for use from BCM. These materials were developed in former BCM faculty member Norman Greenberg’s laboratory in collaboration with the University of Manitoba in the 1990s. BCM has licensed the mouse model more than 30 times over the years and the cell lines more than 40 times and is still collecting royalties on 18 of those agreements. There is continued interest in industry for both the mouse and cell lines and we signed a number of new TRAMP agreements in FY ’13. The TRAMP mice and cell lines provide a great example of a non-exclusive licensing strategy that has led to widespread commercial use and adoption of a popular model.